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Recently, it has been reported that TLR2 on macrophages plays a unique role in the inﬂammatory response and host defense to
infectionwithBorreliaburgdorferi(Bb)whichisanetiologicagentofLymedisease.ExperimentalstudiesshowthatPMNsalsoplay
an essential role in infection control by Bb. However, there is no available data about TLR2 expression on PMN in the course of
Lyme disease. In the present study, TLR2 expression and production of IL-1β and IL-6 as well as their natural regulators (sIL-1RII,
IL-1Ra and sIL-6Rα, sgp130, resp) by PMN of peripheral blood in patients with Lyme disease were examined. For the purpose
of comparison, the same activity of autologous peripheral blood mononuclear cells (PBMCs) was estimated. An eﬀect of rhIL-15
on TLR2 and cytokine secretion was also studied. Increased TLR2 expression in unstimulated neutrophils suggests an important
role of these cells in mechanism recognition of Bb u r g d o r f e r iin patients with Lyme disease. The relationship between IL-1β and
IL-6 as well as their regulators by unstimulated PMN and PBMC, observed in the present study, may lead to enhanced IL-6-
and to inhibition of IL-1β-mediated reactions in this patient group. Changes in the TLR2 expression after rhIL-15 stimulation
appear to have a favorable eﬀect on mechanism recognition of Bb. The relations between IL-6 and its regulators (sIL-6Rα and
sgp130) as well as between IL-1β and its regulators (IL-1Ra and sIL-1RII) after rhIL-15 stimulation may lead to enhanced IL-1β-
and IL-6-mediated inﬂammatory reactions in the course of Lyme disease.
Copyright © 2006 E. Jablonska and M. Marcinczyk. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
INTRODUCTION
Toll-like receptors (TLRs) are important pattern-recogni-
tion receptors that play an essential role in activating sig-
nal transduction pathways leading to killing and clearance
of pathogens. TLRs recognize highly conserved, pathogen-
coded molecular structures termed pathogen-associated
molecular patterns (PAMPs) [1, 2]. TLRs are members of
the IL-1R superfamily. In cytoplasmic domain, TLRs show
signiﬁcant homology to the IL-1 receptor type I and IL-18
receptor. This domain contains a conserved region called
the Toll/IL-1R (TIR). Recognition of PAMPs by TLRs re-
cruits MyD88, IRAK kinase, and TRAF6 [1]. These adap-
tor molecules mediate the activation of the JNK, p38, ERK
1/2, NF-κB, and phosphoinositide 3-kinase signaling path-
ways leading to activation of inﬂammatory target genes [3].
Eleven human TLRs have been identiﬁed: TLR1, TLR2,
TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, and
TLR11. They are expressed in a wide range of human innate
as well as in adaptive cells [1, 4–6].
Human polymorphonuclear neutrophils (PMNs), the
primary eﬀector cells in the ﬁrst line of defense infection
factors, express nine of all identiﬁed TLRs except for TLR3
[4, 7]. Among the extensively characterized receptors, TLR2
is crucial for the inﬂammatory response to components of
gram-positive and gram-negative bacteria and mycobacte-
ria such as PGN, lipoteichoic acid, bacterial lipoproteins,
lipopeptides, and lipoarabinomannan [7–9].
Recently, it has been reported that TLR2 on macrophages
mediates responses to lipoproteins of Borrelia burgdorferi,
which is an etiologic agent of Lyme disease. Experimental
studies show that PMNs play a critical role in infection con-
trol by Bb through their phagocytosis both in presence and
in absence of speciﬁc antibody [10]. However, there is no
available data about TLR2 expression in PMN of patients
with Lyme disease. It was well established that PMN besides
phagocytosis can synthesize and release a wide range of in-
ﬂammatory cytokines such as IL-1β, IL-6, IL-8, IL-15, or
TNF-α [11–13]. Available data indicates that activation of
TLRscantriggerthereleaseofcytokinesandchemokines[7].2 Mediators of Inﬂammation
It has been reported that PMNs have also ability to re-
leasecytokine-regulatoryproteinsthatmaycontroltheactiv-
ityofcertaincytokinesinbiologicalﬂuidsorintissueculture.
PMNs are capable of producing soluble IL-1 receptor type II
(sIL-1RII) that retains its aﬃnity for IL-1 ligand but does not
transduce the signal and thus is regarded as an IL-1 inhibitor
[14]. Human PMN can also generate receptor-binding an-
tagonists, such as IL-1Ra that competitively inhibits binding
of IL-1β to IL-1 receptors without exhibiting detectable ago-
nist activity [14]. Furthermore, it was well documented that
PMNsreleaseIL-6regulators:solubleIL-6receptorα(sIL-6R
α) that acts as IL-6 agonist and soluble gp130 (sgp130) that
acts as IL-6 antagonist [15].
The ability of PMN to release cytokines and their natu-
ral regulators is controlled by a wide range of other cytokines
[13–16].ItwaswellestablishedthatIL-15playsanimportant
roleintheinnateimmunityandpotentiatesseveralfunctions
of normal neutrophils [13, 17].Our previous study indicated
the modulatory eﬀect of rhIL-15 on the PMN chemotaxis
and phagocytosis in patients with Lyme disease [12]. More-
over, during other earlier examinations, we showed an IL-
15 inﬂuence on IL-1β and IL-1Ra secretion by PMN from
healthy subjects [17].
In the present study, TLR2 expression in relation to ex-
pression and production of IL-1β, IL-6, as well as their
natural regulators (sIL-1RII, IL-1Ra and sIL-6Rα, sgp130,
resp) production by PMN of peripheral blood in patients
with Lyme disease were estimated. For the purpose of com-
parison, the same activity of autologous peripheral blood
mononuclear cells (PBMCs) was studied. RhIL-15 eﬀect on
TLR2 expression and production of cytokines was also ex-
amined. TLR2 expression in relation to proinﬂammatory cy-
tokinesmayexplainitsroleinthemaintenanceofbalancebe-
tween these mediators. Furthermore, relations between these
molecules after rhIL-15 stimulation may provide new data
on this cytokine disease.
MATERIAL AND METHODS
Patients
A total of 43 patients diagnosed with Lyme borreliosis and
treatedintheDepartmentofParasiticDiseasesandNeuroin-
fections, Medical University of Bialystok, were enrolled into
the study. There were 28 males and 12 females aged from
32 to 55 years. Erythema migrans was found in 2 patients,
neuroboreliosis in 8, Lyme arthritis in 19, and boreliosis in
14. The diagnosis was established based on serologic tests
for IgM and IgG antibodies to Borrelia burgdorferi ﬂagellum
antigen.
Most of patients had increased leukocytosis. The mean
number of white cells in blood was 7.023/μl (from 3.8 to
24.753/μl). The mean percent of PMN in the peripheral
blood of patients was 58.9% (from 34 to 73%).
Blood samples were taken from each patient before treat-
ment.
Control
Control subjects (n = 30) were healthy people aged from 32
to 53 years.
PMNculture
Cells were isolated from heparinized (10U/mL) whole blood
by Gradisol G gradient 1.115g/mL (Polfa) by Zeman et al.
This method enables simultaneous separation of two highly
puriﬁed leukocyte fractions: mononuclear cells (PBMCs),
containing 95% lymphocytes, and polymorphonuclear cells
containing 94% neutrophils (PMNs). The purity of isolated
PMNs was determined by May-Grunewald-Giemsa staining.
The cells were suspended in the culture medium (RPMI-
1640, autologous serum, penicillin, and streptomycin) to
provide 5 ×106 cells/mL and the cells were incubated in ﬂat-
bottomed 96-well plates (Microtest III-Falcon) for 18h at
37◦C in a humidiﬁed incubator with 5% CO2 ( NuAire Sys-
tems, Inc, Tenn, USA). LPS (10μg/mL; Difco, Detroit, Mich,
USA) was tested to stimulate secretion by PMN. RhIL-15
(50ng/mL; R & D Systems) was tested to stimulate secretion
by PMN and PBMC. After culture, the viability of the PMN
was > 90%, PBMC > 92% as determined by trypan blue ex-
clusion.
After 18h incubation, supernatants were removed and
assessed for IL-1β, IL-6, sIL-1RII, IL-1Ra, sIL-6Ra, and
sgp130 using ELISA kit (BioSource International, Inc, Ca-
marillo, USA).
Westernblotanalysis
Cytoplasmic protein fractions of PMN and PBMC were an-
alyzed for the presence of TLR2, IL-1β, sIL-1RII, IL-1Ra and
IL-6,sIL-6Ra,sgp130bywesternblotting.Cellswerelyseddi-
rectlyinthepresenceofinhibitorprotease(Sigma)bysonica-
tion using Vibra-Cell UltrasonicProcessor(Sonics & Materi-
als, Inc, USA). Protein fractions were suspended in Laemmli
buﬀer (Bio-Rad Laboratories, Herkules, Calif, USA) and
then were electrophorezed on SDS-PAGE. The resolved pro-
tein was transferred onto 0.2μm pore-sized nitrocellulose
(Bio-Rad Laboratories, Herkules, Calif, USA). The nitrocel-
lulose was incubated at +4◦C for 18h with the primary mon-
oclonal antibody anti-TLR2 (Alexis, Carlsbad, Calif, USA),
anti-IL-1β, anti-sIL-1RII, anti-IL-1Ra, anti-IL-6, anti-sIL-
6Ra, and anti-sgp130 (R & D Systems, Minneapolis, USA).
After washing with 0.1% TBS-T, the membrane was incu-
bated at room temperature for 1h with alkaline phosphatase
antimouse IgG Abs (Vector Laboratories, Burlingame, Calif,
USA). Immunoreactive protein bands were visualized fol-
lowing the addition of AP-Conjugate Substrate Kit (Bio-
Rad Laboratories, Herkules, Calif, USA). Band intensity was
quantiﬁed using LabImage 1D gel software.
IL-1β,IL-6,sIL-1RII,IL-1Ra,sIL-6Ra,and
sgp130intheserum
IL-1β, IL-6, sIL-1RII, IL-1Ra, sIL-6Ra, and sgp130 levels
in the serum were assessed using ELISA kit (BioSource
International, Inc, Camarillo, USA).
Statisticalanalysis
Theresultsincludingcytokinesareexpressedasmean+stan-
dard deviation. Data was analyzed according to the nonpara-
metric U Mann-Whitney test. Correlations were calculatedE. Jablonska and M. Marcinczyk 3
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Figure 1: Western blot analysis of TLR2 and IL-1β, sIL-1RII, IL-1Ra, IL-6, sIL-6Rα, sgp130 in human PMN and PBMC cells from control
and patients with Lyme disease. a: PMN of control. b: PMN+LPS of control. c: PMN+rhIL-15 of control. d: PMN of patients. e: PMN+LPS
of patients. f: PMN+rhIL-15 of patients. g: PBMC of control. h: PBMC+LPS of control. i: PBMC+rhIL-15 of control. j: PBMC of patients.
k: PBMC+LPS of patients. l: PBMC+rhIL-15 of patients.
using Pearson’s test. A P value less than .05 was considered
statistically signiﬁcant.
RESULTS
Westernblotanalysis
Western blot analysis showed that the samples of unstim-
ulated PMN and PBMC contained a 86kd protein that
was stained by an anti-TLR2 monoclonal antibody (Figure
1(A,A )). These samples also contained 17kd protein stained
by an anti-IL-1β (Figure 1(B,B )), 45kd protein stained by
an anti-sIL-1RII (Figure 1(C,C )), 18kd protein stained by
an anti-IL-1Ra (Figure 1(D,D )), 26kd protein stained by an
anti-IL-6 (Figure 1(E,E )), 55kd protein stained by an anti-
sIL-6Rα (Figure 1(F,F )), and 90–110kd protein stained by
an anti-sgp130 (Figure 1(G,G )).
TherhIL-15-stimulatedPMNandPBMCofpatientscells
expressed an increase of TLR2 protein in comparison with
the unstimulated cells (Figure 1(A,A )). Incubated PMN and
PBMC of patients with rhIL-15 showed higer expression of
IL-1β compared to unstimulated cells (Figure 1(B,B )). In
contrast to PBMC, sIL-1RII expression in PMN of patients
was on the same level as in unstimulated cells in this group
(Figure 1(C,C )). The bands of IL-1Ra and IL-6 in rhIL-15-
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Table 1: IL-1β, sIL-1RII, and IL-1Ra in the culture supernatants of
PMN and PBMC from control and patients with Lyme disease.
Control n = 30 Patients n = 43
PMN PBMC PMN PBMC
¯ x ±SD ¯ x ±SD ¯ x ±SD ¯ x ±SD
IL-1β (pg/mL)
Unstimulated cells 7 ±3.71 3 ±7b 8.8 ±2.81 8 ±3.9b
LPS-stimulated 22 ±7.6a 46 ±13ab 13 ±4.9a∗ 39 ±12ab
rhIL-15 stimulated 28 ±10a 40 ±14ab 11 ±3a∗ 32 ±10ab
sIL-1RII (ng/mL)
Unstimulated cells 0.6 ±0.20 .6 ±0.2 0.9 ±0.5∗ 1 ±0.4b∗
LPS-stimulated 1 ±0.2a 1 ±0.3a 1 ±0.51 .7 ±0.4b∗
rhIL-15 stimulated 0.9 ±0.3a 0.9 ±0.2a 1 ±0.51 .6 ±0.5b∗
IL-1Ra (ng/mL)
Unstimulated cells 0.6 ±0.20 .5 ±0.2 0.6 ±0.30 .4 ±0.2
LPS-stimulated 1 ±0.4a 1 ±0.4a 0.8 ±0.3a 1 ±0.7a
rhIL-15 stimulated 1 ±0.3a 1 ±0.3a 1.4 ±0.4a 1.8 ±0.9a
∗Statistical diﬀerences between control and patients groups
(P<. 001).
aStatistical diﬀerences between unstimulated cells and cells
incubated with LPS or rhIL-15 (P<. 001).
bStatistical diﬀerences between PMN and PBMC (P<. 001).
as in unstimulated cells too (Figure 1(D,D ,E )). Expression
ofIL-6andsIL-6RαinPMNwashigherincomparisontoun-
stimulatedcellsinpatientsgroup(Figure 1(E,F)).Therewere
not any diﬀerences between expression of sgp130 in PMN
and PBMC from patients between unstimulated and stimu-
lated with rhIL-15 (Figure 1(G,G )).
Cytokinesconcentrationsintheculture
supernatantsofPMNandPBMC
In the culture supernatants of PMN and PBMC, we did not
ﬁnd diﬀerences in the concentrations of IL-1β and IL-1Ra
between patients and the control group (Table 1). In both
groups, stimulation with rhIL-15 or LPS induced signiﬁcant
increase in IL-1β and IL-1Ra release. Concentrations of IL-
1β in culture supernatants of stimulated PMN of patients
were statistically lower than those in cultures of the control
group. We also found higher concentrations of IL-1β in cul-
ture supernatants of PBMC as compared to PMN of control
andpatientgroups(Table 1).Incontrast,unstimulatedPMN
and unstimulated and stimulated PBMC from patients with
LymediseasesecretedhigherconcentrationsofsIL-1RIIthan
the cells from healthy subjects (Table 1). The release of sIL-
1RII was not signiﬁcantly diﬀerent in cultures of unstimu-
lated and stimulated PMN and PBMC in patients.
Unstimulated and rhIL-15-stimulated PMN and PBMC
from patients with Lyme disease secreted higher concentra-
tionsofIL-6thancellsfromhealthycontrol(Table 2).These-
cretionofsIL-6RαbyunstimulatedPMNandPBMCwasnot
signiﬁcantly diﬀerent between patient and control groups
Table 2: IL-6, sIL-6Rα, and sgp130 in the culture supernatants of
PMN and PBMC from control and patients with Lyme disease.
Control n = 30 Patients n = 43
PMN PBMC PMN PBMC
¯ x ±SD ¯ x ±SD ¯ x ±SD ¯ x ±SD
IL-6 (pg/mL)
Unstimulated cells 8 ±3.32 4 ±4.7b 19 ±8.3∗ 39 ±14b∗
LPS-stimulated 16 ±3.8a 39 ±9.0ab 21 ±6.54 3 ±13b
rhIL-15 stimulated 11 ±2.7a 29 ±6.1b 26 ±9.3a∗ 42 ±12b∗
sIL-6Rα (ng/mL)
Unstimulated cells 2.3 ± 0.94 ±1.4b 1.6 ±0.93 ±0.9b
LPS-stimulated 3.9 ±1.0a 5.4 ±2.1 2.2 ± 0.8a∗ 3.5 ±0.9b∗
rhIL-15 stimulated 3 ±0.85 .2 ±1.9b 2 ±0.5a 3.4 ±0.6ab∗
sgp130 (ng/mL)
Unstimulated cells 29 ±9.23 1 ±6.4 28 ±6.72 7 ±8.4∗
LPS-stimulated 42 ±10a 44 ±12a 37 ±10a 37 ±12a
rhIL-15 stimulated 33 ±8.73 6 ±6.7 30 ±8.23 3 ±7.3∗
∗Statistical diﬀerences between control and patients groups
(P<. 001).
aStatistical diﬀerences between unstimulated cells and cells
incubated with LPS or rhIL-15 (P<. 001).
bStatistical diﬀerences between PMN and PBMC (P<. 001).
(Table 2). PMN and PBMC from patients treated with rhIL-
15producedhigheramountsofsIL-6Rαthanuntreatedcells.
Themeanvalueofsgp130 inculturesupernatantsofunstim-
ulated and stimulated PMN and PBMC was not signiﬁcantly
diﬀerent between patient and control groups.
Cytokinesconcentrationsintheserum
The concentrations of IL-1β, IL-1Ra, IL-6, sIL-6Rα, sgp130,
and IL-15 in the serum of patients with Lyme disease were
signiﬁcantly higher than those in the serum of control group
(Table 3).
Relationshipsbetweenestimatedcytokinesin
culturesupernatantsofcellsandtheserum
Although there was no correlation between IL-1β,I L - 1 R a ,
IL-6 and their receptors release by PMN, PBMC and the
serum levels in patients with Lyme disease, a coincidence be-
tween them was found. This appears to suggest that other
cells are also responsible for their concentrations in sera of
this patient group. In contrast, a direct correlation between
the release of sIL-1RII by PBMC and sera levels was shown
indicating that these cells are main source of circulating sIL-
1RII (r = 0.63, P<. 05).
DISCUSSION
In the present study, changes in TLR2 expression and cy-
tokine production in freshly isolated PMN and PBMC from
patients with Lyme disease before treatment were found.E. Jablonska and M. Marcinczyk 5
Table 3: The mean concentrations of IL-1β, sIL-1RII, IL-1Ra, IL-6,
sIL-6Rα,andsgp130intheserumofcontrolandpatientswithLyme
disease.
Serum
Control n = 30 Patients n = 43
¯ x ±SD ¯ x ±SD
IL-1β (pg/mL) 3.7 ±1.43 6 ±10∗
sIL-1RII (ng/mL) 4.1 ±1.64 .3 ±1.2
IL-1Ra (ng/mL) 0.4 ±0.10 .8 ±0.3∗
IL-6 (pg/mL) 5.3 ±0.91 2 ±5.5∗
sIL-6R (ng/mL) 14 ±6.75 6 ±5.1∗
sgp130 (ng/mL) 37 ±5.97 2 ±8.1∗
IL-15 (pg/mL) 290 ±91 383 ±101∗
∗Statistical diﬀerences between control and patients group (P<. 001).
Increased expression of TLR2 in PMN and PBMC may
lead to enhance the mechanism recognition of spirochetes B
burgdorferi and their elimination. Signiﬁcant role of TLR2 in
the control of Bb u r g d o rf e riinfection was conﬁrmed by a fact
that deﬁciency in TLR2 greatly impaired the host defense to
Bb, resulting in more number of spirochetes in tissues [18].
High expression of TLR2 in PMN and PBMC from pa-
tients may be caused by outer surface lipoproteins of B
burgdorferi such as OspA or OspB in vivo [8, 19]. It has been
demonstrated that TLR2-expressing macrophages are stim-
ulated by Bb suggesting that TLR2 recognition of lipopro-
teins is relevant to natural Borrelia infection [19]. Results
of Bulut et al have shown that Bb outer surface lipoprotein
A (OspA-L) signals through TLR2 [8]. They also found that
OspA-L requires functional cooperation of TLR6 and TLR2
to signal transduction. This combination of TLRs facilitates
mammalian responsiveness to a wide array of pathogen-
associated molecular patterns and diversiﬁes the repertoire
of Toll-mediated responses [20].
Despite the increase in TLR2 expression, elevated IL-6
production by examined leukocytes was also observed. Si-
multaneous enhanced TLR2 expression and IL-6 production
by examined cells suggest that TLR2 engagement can up-
regulate neutrophil inﬂammatory cytokine production. This
is in agreement with data, indicating that TLR2 signal trig-
gers expression of inﬂammatory cytokines, involving IL-6
[21].
Similar to TLR2 are lipoproteins of Bb u r g d o r f e r ithat
possess cytokine-stimulating properties and may be respon-
sible for enhanced secretion of IL-6 by PMN and PBMC
of patients with Lyme diseases [16]. Increased IL-6 produc-
tion by these cells from patients may enhance the inﬂamma-
tory reactions leading to Bb u r g d o r f e r ielimination. On the
other hand, elevated IL-6 activity can make a contribution
to long-lasting inﬂammatory process in patients with Lyme
diseaseespeciallythatitsinhibitor—sgp130—releasewasun-
changed.
In contrast to IL-6 family proteins, unchanged pro-
duction of IL-1β was associated with high secretion of its
inhibitor—sIL-1RII by PMN and PBMC of patient group.
Lack of signiﬁcant alteration in secretion of IL-1β may be
caused by a suppressive eﬀect of IL-6. In contrast, IL-1β has
ability to enhance the IL-6 production by immune cells [22].
Furthermore, increased sIL-1RII production by these cells,
acting as inhibitor for IL-1β, may lead to decrease its ac-
tivity in patient with Lyme disease. Thus, unchanged secre-
tion of IL-1β together with increased secretion of sIL-1RII
by PMN may be a protect mechanism of host against exces-
sive activity of IL-6 in early phase of inﬂammation. In con-
trast, the studies curried out by Brown et al suggest that sIL-
1RIIplaysanimportant roleinthelateinﬂammation,specif-
ically working as a reservoir for remaining IL-1β and pre-
venting the change of extracellular pro-IL-1β into active IL-
1β [23]. Furthermore, unchanged IL-1Ra secretion by PMN
and PBMC can be one of the host defense mechanism to in-
ﬂammatory process. Several studies showed that IL-1Ra re-
duced markedly the inﬁltration of inﬂammatory cells to tis-
sue sites [24]. Moreover, IL-1Ra can inhibit IL-8 secretion
by PBMC induced by IL-18 [25]. Interesting data including
IL-1β and IL-1Ra in patients with Lyme disease by Miller et
al was found [26]. They suggested that relationship between
theseproteinsinﬂuencesprogressionofLymearthritis.How-
ever, we did not ﬁnd distinct relations between IL1β and IL-
1RainpatientswithLymearthritisincomparisontopatients
with neuroborreliosis, borreliosis, or erythema migrans.
Increased TLR2 and cytokines expression can be con-
trolled by other cytokines. For example, it was well estab-
lished that TLR2 on monocytes is upregulated by IL-1 [27].
A new role of IL-15 in the regulation of human TLR2
expression was shown for the ﬁrst time, by our results
showing an eﬀect of rhIL-15 on its increased expression in
PMN and PBMC in vitro. This data is similar to results of
Musikacharoen et al who reported that mouse TLR2 mRNA
was rapidly induced by IL-15 [27].
It is interesting to note increased secretion of IL-6 and
its agonist sIL-6Ra by PMN and PBMC after rhIL-15 stimu-
lation leading to enhance IL-6-mediated response in patients
withLymedisease.Incontrast,increasedproductionofIL-1β
by cells stimulated with rhIL-15 is balanced by simultaneous
increased secretion of its antagonist—IL-1Ra that can block
IL-1β-mediated reactions.
Concluding, increased TLR2 expression in neutrophils of
patients with Lyme disease indicates an important role of
thesecellsinrecognitionofBburgdorferi.TLR2expressionin
relation to expression and production of cytokines and their
regulators suggests a role of this receptor in enhanced IL-6-
and inhibition of IL-1β-mediated reactions in patients with
Lyme disease. Changes in the TLR2 expression after rhIL-
15 stimulation suggest a favorable eﬀect of this cytokine on
mechanism recognition of Bb by PMN and PBMC. In con-
trast, changes in the release of IL-6 and sIL-6Ra after rhIL-
15 stimulation suggest an unfavorable eﬀect of this cytokine
leading to enhance IL-6 activity in the course of Lyme dis-
ease. Observations above clearly suggest that further exami-
nations are needed to explain an actual role of IL-15 in im-
mune and inﬂammatory response during infection control
by B burgdorferi.6 Mediators of Inﬂammation
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